AR093457A1 - Derivados de bendamustina y metodos para utilizarlos - Google Patents

Derivados de bendamustina y metodos para utilizarlos

Info

Publication number
AR093457A1
AR093457A1 ARP130104160A ARP130104160A AR093457A1 AR 093457 A1 AR093457 A1 AR 093457A1 AR P130104160 A ARP130104160 A AR P130104160A AR P130104160 A ARP130104160 A AR P130104160A AR 093457 A1 AR093457 A1 AR 093457A1
Authority
AR
Argentina
Prior art keywords
methods
bendamustine
bendamustine derivatives
derivatives
amides
Prior art date
Application number
ARP130104160A
Other languages
English (en)
Spanish (es)
Inventor
P Bakale Roger
Chen Jian
Y Labell Rachel
R Patel Piyush
d brown Peter
S Drager Anthony
E Mkean Robert
C Roemmele Renee
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR093457A1 publication Critical patent/AR093457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP130104160A 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos AR093457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR093457A1 true AR093457A1 (es) 2015-06-10

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104160A AR093457A1 (es) 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos

Country Status (17)

Country Link
US (7) US9452988B2 (https=)
EP (1) EP2917183A1 (https=)
JP (1) JP6262246B2 (https=)
KR (1) KR20150086308A (https=)
AR (1) AR093457A1 (https=)
AU (1) AU2013342015B2 (https=)
BR (1) BR112015010501A2 (https=)
CA (1) CA2890462A1 (https=)
CL (1) CL2015001246A1 (https=)
EA (1) EA029706B1 (https=)
HK (2) HK1212977A1 (https=)
IL (1) IL238662A (https=)
MX (1) MX2015005805A (https=)
PH (1) PH12015501024A1 (https=)
SG (1) SG11201503560TA (https=)
TW (1) TWI598341B (https=)
WO (1) WO2014075035A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
KR20150086308A (ko) 2012-11-12 2015-07-27 이그니타, 인코포레이티드 벤다무스틴 유도체 및 그의 사용 방법
ES2670995T3 (es) 2013-03-12 2018-06-04 Cephalon, Inc. Formulaciones de nanopartículas y macropartículas
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
EP3484519A1 (en) * 2016-07-13 2019-05-22 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2428018A1 (en) 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
US20060165987A1 (en) * 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP2222278B1 (en) * 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
MX2011003751A (es) * 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
JO3587B1 (ar) 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
KR101955065B1 (ko) 2012-06-19 2019-03-06 헬무트 쉬카네더 벤다무스틴 유도체 및 관련 화합물, 및 이의 암 치료 의약 용도
CN104736181A (zh) 2012-08-10 2015-06-24 北德克萨斯大学健康科学中心 包含靶向聚氨基酸与脂肪酸之缀合物的药物递送载剂
KR20150086308A (ko) * 2012-11-12 2015-07-27 이그니타, 인코포레이티드 벤다무스틴 유도체 및 그의 사용 방법

Also Published As

Publication number Publication date
KR20150086308A (ko) 2015-07-27
EA201590925A1 (ru) 2015-09-30
MX2015005805A (es) 2016-04-15
SG11201503560TA (en) 2015-06-29
US20180147186A1 (en) 2018-05-31
IL238662A (en) 2017-08-31
EP2917183A1 (en) 2015-09-16
AU2013342015A1 (en) 2015-05-28
IL238662A0 (en) 2015-06-30
CN105051016A (zh) 2015-11-11
WO2014075035A1 (en) 2014-05-15
CA2890462A1 (en) 2014-05-15
US9452988B2 (en) 2016-09-27
EA029706B1 (ru) 2018-05-31
US20160016912A1 (en) 2016-01-21
JP2015536996A (ja) 2015-12-24
US20150246023A1 (en) 2015-09-03
US9913827B2 (en) 2018-03-13
US9150517B2 (en) 2015-10-06
AU2013342015B2 (en) 2016-11-24
PH12015501024A1 (en) 2015-07-27
CL2015001246A1 (es) 2016-01-15
US20150232427A1 (en) 2015-08-20
US20160289198A1 (en) 2016-10-06
HK1212977A1 (zh) 2016-06-24
BR112015010501A2 (pt) 2017-07-11
TWI598341B (zh) 2017-09-11
US20150274675A1 (en) 2015-10-01
JP6262246B2 (ja) 2018-01-17
TW201439069A (zh) 2014-10-16
HK1215701A1 (zh) 2016-09-09
US9149464B2 (en) 2015-10-06
US9630926B2 (en) 2017-04-25
US20170182008A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
AR093457A1 (es) Derivados de bendamustina y metodos para utilizarlos
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
MX367389B (es) Compuestos y sus metodos de empleo.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
CR20170500A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CO7350620A2 (es) Nuevos derivados de piridina
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
UY34523A (es) Derivados de betulina
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
UY33884A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20150447A (es) Nuevos derivados de pirazol
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
IN2014DN10214A (https=)

Legal Events

Date Code Title Description
FB Suspension of granting procedure